Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)

Lori J. Goldstein; Raymond P. Perez; Denise Yardley; Linda K. Han; James M. Reuben; Hui Gao; Susan McCanna; Beth Butler; Pier Adelchi Ruffini; Yi Liu; Roberto R. Rosato; Jenny C. Chang

doi:10.1186/s13058-020-01294-7

Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)

Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang

Hematopathology

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

After publication of the original article [1], the authors identified two errors in the Author details: 1. Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley's affiliation in addition to Tennessee Oncology. 2. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.

Original language	English (US)
Article number	52
Journal	Breast Cancer Research
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s13058-020-01294-7
State	Published - May 20 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1186/s13058-020-01294-7

Cite this

Goldstein, L. J., Perez, R. P., Yardley, D., Han, L. K., Reuben, J. M., Gao, H., McCanna, S., Butler, B., Ruffini, P. A., Liu, Y., Rosato, R. R., & Chang, J. C. (2020). Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8). Breast Cancer Research, 22(1), Article 52. https://doi.org/10.1186/s13058-020-01294-7

Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8). / Goldstein, Lori J.; Perez, Raymond P.; Yardley, Denise et al.
In: Breast Cancer Research, Vol. 22, No. 1, 52, 20.05.2020.

Research output: Contribution to journal › Comment/debate › peer-review

Goldstein, LJ, Perez, RP, Yardley, D, Han, LK, Reuben, JM, Gao, H, McCanna, S, Butler, B, Ruffini, PA, Liu, Y, Rosato, RR & Chang, JC 2020, 'Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)', Breast Cancer Research, vol. 22, no. 1, 52. https://doi.org/10.1186/s13058-020-01294-7

@article{156e3b92af274916b42a09bb9f377340,

title = "Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)",

abstract = "After publication of the original article [1], the authors identified two errors in the Author details: 1. Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley's affiliation in addition to Tennessee Oncology. 2. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.",

author = "Goldstein, {Lori J.} and Perez, {Raymond P.} and Denise Yardley and Han, {Linda K.} and Reuben, {James M.} and Hui Gao and Susan McCanna and Beth Butler and Ruffini, {Pier Adelchi} and Yi Liu and Rosato, {Roberto R.} and Chang, {Jenny C.}",

year = "2020",

month = may,

day = "20",

doi = "10.1186/s13058-020-01294-7",

language = "English (US)",

volume = "22",

journal = "Breast Cancer Research",

issn = "1465-5411",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Erratum

T2 - A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)

AU - Goldstein, Lori J.

AU - Perez, Raymond P.

AU - Yardley, Denise

AU - Han, Linda K.

AU - Reuben, James M.

AU - Gao, Hui

AU - McCanna, Susan

AU - Butler, Beth

AU - Ruffini, Pier Adelchi

AU - Liu, Yi

AU - Rosato, Roberto R.

AU - Chang, Jenny C.

PY - 2020/5/20

Y1 - 2020/5/20

N2 - After publication of the original article [1], the authors identified two errors in the Author details: 1. Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley's affiliation in addition to Tennessee Oncology. 2. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.

AB - After publication of the original article [1], the authors identified two errors in the Author details: 1. Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley's affiliation in addition to Tennessee Oncology. 2. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.

UR - http://www.scopus.com/inward/record.url?scp=85085156909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085156909&partnerID=8YFLogxK

U2 - 10.1186/s13058-020-01294-7

DO - 10.1186/s13058-020-01294-7

M3 - Comment/debate

C2 - 32434589

AN - SCOPUS:85085156909

SN - 1465-5411

VL - 22

JO - Breast Cancer Research

JF - Breast Cancer Research

IS - 1

M1 - 52

ER -

Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this